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Breast cancer is one of the most common cancers and the second most responsible 
for cancer mortality worldwide. In 2014, in Portugal approximately 27,200 people died 
of cancer, of which 1,791 were women with breast cancer. Flaxseed has been one of 
the most studied foods, regarding possible relations to breast cancer, though mainly 
in experimental studies in animals, yet in few clinical trials. It is rich in omega-3 fatty 
acids, α-linolenic acid, lignan, and fibers. One of the main components of flaxseed is 
the lignans, of which 95% are made of the predominant secoisolariciresinol diglucoside 
(SDG). SDG is converted into enterolactone and enterodiol, both with antiestrogen 
activity and structurally similar to estrogen; they can bind to cell receptors, decreasing 
cell growth. Some studies have shown that the intake of omega-3 fatty acids is related 
to the reduction of breast cancer risk. In animal studies, α-linolenic acids have been 
shown to be able to suppress growth, size, and proliferation of cancer cells and also to 
promote breast cancer cell death. Other animal studies found that the intake of flaxseed 
combined with tamoxifen can reduce tumor size to a greater extent than taking tamoxifen 
alone. Additionally, some clinical trials showed that flaxseed can have an important role 
in decreasing breast cancer risk, mainly in postmenopausal women. Further studies are 
needed, specifically clinical trials that may demonstrate the potential benefits of flaxseed 
in breast cancer.
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iNTRODUCTiON
Cancer is one of the most serious health problems in Public Health given its high and increasing 
prevalence worldwide, being one of the main causes of morbidity and mortality and also responsible 
for a significant decrease in life quality. According to the World Health Organization (WHO), in 
2012, 14 million new cases of cancer were diagnosed, which were responsible for 8.2 million deaths 
worldwide, with 521,000 of them being attributed to breast cancer (1–3).
In 2012, it was estimated that approximately 32.5 million people were cancer survivors, 5 years 
after being diagnosed with the disease. In 2030, it is expected that approximately 23.6 million new 
cases of cancer will be diagnosed each year (4).
In 2014, in Portugal approximately 27,200 people died of cancer, of which 16,600 were men and 
10,600 were women (2).
According to the WHO, approximately one-third of the deaths caused by cancer are due to bad 
eating habits and lack of physical activity. By improving eating habits and increasing physical activity, 
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more than 30% of the cancers diagnosed could be avoided. Thus, 
with the increased risk, a proper nutrition intervention is neces-
sary (1–3).
Nutrition plays a fundamental role in cancer, as it can reduce 
complications that happen during treatment and can contribute 
to the patient’s well-being (3, 5).
Many people with cancer choose to make some changes in 
their eating habits while subjected to conventional, like chemo-
therapy. The patients do this in the hopes of decreasing the treat-
ment’s severe side effects such as anxiety, depression, insomnia, 
headaches, nausea, and vomiting (among others) (6–9).
These less-conventional treatments may include diets with 
food that has proper nutritional characteristics to help fight the 
disease. Flaxseed has been one of the most studied foods regarding 
the possible relation to breast cancer. Some experimental studies 
in animals have been done but few progressed to clinical trials.
MATeRiALS AND MeTHODS
To review the effect flaxseed may have in breast cancer, we 
conducted a bibliography research using sources from PubMed, 
and websites of institutions like Cancer Research UK and the 
WHO. The keywords used in the research were as follows: cancer, 
flaxseed, lignan, breast cancer, and nutrition.
ReSULTS
Breast Cancer
Breast cancer is considered as one of the most common cancers 
with the highest number of deaths worldwide. According to the 
WHO, it was estimated that in 2012, more than 1.68 million of 
women were diagnosed with breast cancer worldwide. Of these, 
approximately 521,000 died and in Europe, during the same year, 
more than 464,000 new cases were diagnosed and approximately 
131,000 women died (1, 10, 11).
In 2014, in the United Kingdom, there were approximately 
55,200 new cases of breast cancer (390 men and about 54,800 
women), of which approximately 150 were diagnosed daily with 
approximately 11,400 deaths due to this kind of cancer. It is con-
sidered that one in eight women will be diagnosed with breast 
cancer during their lifetime (11).
In 2014, in Portugal, approximately 27,200 people died of 
cancer, with 1,791 of the victims being women with breast can-
cer. Also, approximately 6,088 new cases of breast cancer were 
diagnosed in women (2).
There are several factors that can be associated with breast 
cancer, such as gender, bad eating habits and respective lifestyles, 
family history, alcohol or tobacco consumption, lack of breast 
feeding, hormone treatments, overweight, and obesity, among 
others (10, 11).
After being diagnosed, many patients with breast cancer decide 
to change their eating habits and respective lifestyles (12, 13).
Flaxseed and the Lignans
Flax (Linum usitatissimum), also known as linseed, belongs to 
the Linaceae family which originates from Europe, Asia, and the 
Mediterranean region. Flaxseed can be divided in two species: 
brown and golden. Golden flax develops in very cold climates, 
while brown flax develops in warmer and more humid climates. 
The latter must be ground to be better digested and absorbed by 
the body, thus increasing the bioavailability of the nutrients. It 
is considered a functional food that has nutrients with specific 
properties (antioxidant and/or antitumorigenic functions), such 
as omega-3 fatty acids, α-linolenic acid (LA), lignan, or fibers 
that are beneficial to one’s health, preventing some diseases, such 
as cancer and cardiovascular diseases, among others (14–16). 
Flaxseeds are rich in fiber and are suggested for situations of 
constipation, as they help to improve the intestinal function. They 
have omega-3 fatty acids that promote the reduction of cholesterol 
levels, thus preventing cardiovascular diseases. Additionally, they 
are still a good source of magnesium, phosphorus, manganese, 
vitamin B1, selenium, and zinc.
Although they are defined as one of the richest plant sources 
in omega-3 fatty acids, these seeds are also characterized by 
their lignan content. Although lignans are found in a variety of 
vegetable sources, such as whole grains, sesame seeds, vegetables, 
and fruits, flaxseeds have approximately 100 times more lignans 
than other foods (9, 17, 18).
Lignans are phytoestrogens that relieve the symptoms of 
menopause and can balance the effects of estrogen in the body by 
connecting to their receptors, as they have a very similar chemical 
structure as to an estrogen molecule (19).
The predominant lignan in flaxseeds is secoisolariciresinol 
diglucoside (SDG), making up around 95% of the seed’s lignan 
content. The remaining 5% consist of lariciresinol, pinoresinol, 
and matairesinol. After SDG lignan ingestion, bacteria in the 
colon act by converting the lignan into mammalian lignans, 
enterolactone, and enterodiol. These are structurally similar to 
estrogen, and have antioxidant activity and a weak estrogenic 
action (Figure 1). It also works as an antiestrogenic because its 
structure is very similar to the main form of estrogen, which 
allows its binding to the cell’s receptors, thus inhibiting the 
growth of cancer cells (9, 20–23).
Breast tumors that contain estrogen receptors are called 
estrogen receptor positive (ER+) and tumors that lack estrogen 
receptors are estrogen receptor negative (ER−). Women who have 
ER+ tumors are more likely to respond to hormonal treatments 
than women with ER− tumors (24).
In our body, the biological active form of estrogen is estra-
diol, which is oxidized mainly in the liver to estrone. Estrone 
can be converted to two metabolites with different biological 
effects: 2-hydroxyestrone (2OHE1) and 16α-hydroxyestrone 
(16OHE1). While the first one has a small biological activity, 
the latter will increase the estrogen’s activity, promoting cell 
proliferation (growth of cancer cells) (Figure 2) (25, 26). Women 
who produce more 16OHE1 are likely to have an increased risk 
of breast cancer (27).
Two clinical trials concluded that 28 postmenopausal women, 
who followed a diet including 10 or 25 g of ground flaxseed for 7 
or 16 weeks, witnessed an increased level of excretion of 2OHE1 
in their urine, without an increase in the excretion of 16OHE1. 
These studies imply that flaxseed can have some protective 
effects in postmenopausal women (28).
FigURe 2 | Influence of estrogen metabolism in cancer cells.
FigURe 1 | Metabolism of lignans in flaxseeds.
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Omega-3 Fatty Acids and Breast Cancer
Polyunsaturated fatty acids (PUFAs) can be composed of omega-3 
and omega-6. Linolenic acid and arachidonic acid (AA) are the 
main components of omega-6. The α-linolenic acid (ALA) is the 
precursor of the PUFA omega-3 family which forms eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA) (29, 30).
Omega-3 and ALA are also constituents of flaxseed. Flaxseed 
is considered as the best plant source of the essential omega-3 
fatty acid. Studies suggest that the omega-3 fatty acid may have 
anticancer properties while omega-6 fatty acid can contribute 
to the development of cancer. Currently, in a regular diet, there 
is a higher amount of omega-3, than omega-6 (29, 30). Studies 
have revealed that PUFA omega-3 ingestion is associated with 
the reduction of risk of breast cancer (31). In animal studies, the 
ALAs have been shown to be able to suppress the growth, size, 
and proliferation of cancer cells. An increase in the death of these 
cells has also been observed (32, 33).
Tamoxifen and Breast Cancer
Tamoxifen is a drug used in the treatment of breast cancer, mainly 
in women with ER+. It can be used as an adjuvant therapy for 
breast cancer or metastatic breast cancer. It is a type of hormone 
therapy that is done during 5–10 years with several side effects 
(34–37).
This drug works as an antiestrogen since, as it is an ER+ type 
of cancer, the tamoxifen acts throughout the whole body, block-
ing the action of estrogen on tumor cells, thus preventing their 
growth (34, 35).
According to experimental studies, flaxseed does not have any 
type of interaction with drugs used in breast cancer treatments 
and can provide an additional protective effect when consumed 
along with the treatment. In animal studies, it was also verified 
that flaxseed, flax oil, or lignan SDG ingestion, in combination 
with tamoxifen, reduced the tumor’s size to a greater extent than 
tamoxifen treatment alone. Until now, there are no clinical trials 
that can prove the benefits that flaxseed ingestion can have in 
women with breast cancer during tamoxifen therapy (38).
A study undertaken at the University of Toronto evaluated the 
effect of flaxseed and tamoxifen, alone and in combination, on 
the growth of ER+ human breast tumor cells in mice. These mice 
were injected with MCF-7 tumors and fed with different diets. 
The diets had 20–25 g of ground flaxseed, a tamoxifen pill (5 mg) 
or both. Tumor growth was monitored weekly. As a result, the 
4Calado et al. The Effect of Flaxseed in Breast Cancer
Frontiers in Nutrition | www.frontiersin.org February 2018 | Volume 5 | Article 4
flaxseed diet fed to the mice was the one that inhibited the growth 
of the ER+ human breast tumor cells. At low 17 beta-estradiol 
levels, flax inhibited tumor size approximately 74%, while at 
high 17 beta-estradiol levels it inhibited approximately to 22%. 
Furthermore, the combination of flax and tamoxifen inhibited 
tumor size more than 53%, as compared with tamoxifen action 
alone (39).
Other experimental studies conducted in mice injected with 
ER+ human breast tumor cells reveal that both at low- and high-
estrogen levels (pre- and postmenopausal breast cancer), flaxseed 
either increased or kept tamoxifen’s effectiveness in decreasing 
tumor growth, cell proliferation, and increased apoptosis (38–42).
There are currently no known results from clinical trials 
regarding flaxseed ingestion during tamoxifen therapy (38).
Animal Studies
In animal studies with mice injected with breast tumor cells, 
feeding them with flaxseed caused a decrease in tumor incidence, 
number, and size. These results were also revealed to be inde-
pendent of the tumor’s stage (23).
A research group from the University of Toronto has also dem-
onstrated that ground flaxseed has an effective anticancer activity. 
Their experimental study was conducted in mice to which tumors 
were administered, along with the introduction in their diet of a 
mixture of lignan. The result was a decrease in the tumor load 
due to the presence of flaxseed and lignan SDG in the mice diet 
(43–45).
Recently, the same research group injected another mice group 
with human breast tumor cells. While the cancer was progress-
ing, the mice were on a regular diet for 8 weeks after cancer cells’ 
injection. One group was fed with 10% of flaxseed, while the other 
group kept the same kind of diet. The rate of the tumor growth 
was reduced by 45% due to flaxseeds (43–45).
In several other experimental studies, diets including 5 or 10% 
of flaxseed (approximately 25–30 g of flaxseed daily, in humans) 
inhibited the growth of the ER+ in human breast cancer cells 
injected in mice (39–42, 46, 47). The same happened with the 
growth of the ER− (44, 48, 49). Flaxseed also reduced metastasis 
of ER− breast tumor (44, 48, 50).
Clinical Trials
Observational studies indicate that flaxseed consumption (appro-
ximately 32 g/daily) can reduce breast cancer risk (38, 51, 52). 
Lignans also contribute to the decrease of breast cancer risk. 
Vegetarians have a higher level of lignan ingestion, meaning that 
their breast cancer risk is lower than that of omnivores (53).
A study revealed that 70% of newly diagnosed patients with 
breast cancer consume food rich in lignans, 52% consume flax 
bread, and 30% consume flaxseed at least once a week (13).
A pilot study including 24 postmenopausal women with 
ER+ breast cancer was conducted to show the effects of flaxseed 
and the aromatase inhibitor, anastrozole (drug used in the treat-
ment of breast cancer), and possible interactions between them in 
selected breast tumor characteristics and serum steroid hormone. 
These women were then divided randomly into four groups: 
Group 1 with 25 g/daily of ground flaxseed and 1 placebo pill daily; 
Group 2 with 1 mg/daily of anastrozole; Group 3 with 25 g/daily 
of ground flaxseed and 1  mg/daily of anastrozole; and Group 
4 with 1 placebo pill daily. This study did not show any effects 
regarding flaxseed on the aromatase inhibitor activity in selected 
breast tumor characteristics and serum steroid hormone levels 
(9). Further studies are needed to support a possible interaction 
between flaxseed intake and the aromatase inhibitor––anastrozole.
Ingestion of flaxseed or bread containing this ingredient is 
associated with a 20% reduction in the risk of breast cancer, in 
accordance with the protective effect observed in lignans from 
other vegetables. This risk decrease may be related to a reduction 
in inflammation, since the presence of large amounts of lignans 
can lead to a decrease in several inflammatory markers (52, 54).
In two meta-analysis studies, it was found that a higher intake 
of lignans from dietary sources was associated with a significant 
reduction in postmenopausal breast cancer risk (54, 55). In a case-
control study, the highest lignan consumption was associated 
with significantly lower postmenopausal breast cancer mortality 
but that association did not happen relatively to premenopausal 
breast cancer mortality (56).
A case-control study using the Ontario cancer registry data-
base consisted of a random sample of women diagnosed with 
breast cancer, with the aim of analyzing the phytoestrogen 
intake (isoflavones and lignans) and their association with breast 
cancer risk. A food-frequency questionnaire was used, which 
also included foods rich in phytoestrogens. Lignan intake was 
associated with a reduction in the risk of breast cancer for all 
women, although this was only statistically significant in over-
weight women (BMI > 25). In premenopausal women, the total 
phytoestrogen intake was associated with a significant reduction 
in the risk of breast cancer, but only in overweight women. There 
was no association between breast cancer risk and the intake of 
phytoestrogen in postmenopausal women (51).
Another case-control study also using the Ontario cancer 
registry database conducted a food-frequency questionnaire 
with the aim of establishing if phytoestrogen intake during ado-
lescence could protect against breast cancer in adulthood. The 
results of this study revealed that a higher phytoestrogen intake 
(isoflavones and lignans) during adolescence can be associated 
with a reduced breast cancer risk (57).
To explore the association between flaxseed ingestion and 
breast cancer risk, a case-control study was conducted by apply-
ing a food-frequency questionnaire to women who joined the 
Ontario Women’s Diet and Health Study in Canada (2002–2003). 
Both the monthly and weekly/daily consumption of flaxseed 
(approximately 32.5 g) and flax bread (1 unit, roughly 2.5 − 5 g of 
flaxseed) were associated with a significant reduction from 18 to 
24% in the risk of breast cancer in all women. It was also showed 
that flaxseed only reduced breast cancer risk in postmenopausal 
women, while flax bread reduced breast cancer risk in both 
postmenopausal and premenopausal women (52).
A prospective cohort study, including 58,049 postmenopausal 
French women, found that those with the highest lignan inges-
tion (>1,395 μg/day) had a significantly decreased risk of breast 
cancer. The beneficial effects of lignans in this study were limited 
to ER+ breast cancer and progesterone receptor positive (58).
On the other hand, researchers conducted a double-blind, 
randomized clinical trial, with a placebo control in patients with 
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breast cancer. The investigators tracked postmenopausal women 
that had been recently diagnosed with breast cancer and with a 
scheduled surgery. These women were then divided, randomly, 
into two groups: Group 1, which included 19 women, ate a muf-
fin daily with approximately 25 g of powdered flaxseed, while 
Group 2, which included 13 women, ate a similar looking muffin, 
without flaxseed. Biopsies were performed in both groups, at 
the beginning of the trial, which were later compared with the 
pathology of the tumor removed during surgery, approximately 
5  weeks after the study began. Women who ate the muffin 
containing flaxseed presented, on average, a decrease in the 
tumor cell proliferation, a reduction in the expression of c-erB2 
levels (also known as HER2––an oncogene associated with the 
development and progression of breast cancer) and an increase 
in cell apoptosis. Researchers concluded that flaxseed has the 
potential of reducing tumor growth in patients with this type of 
cancer (38, 59).
In another clinical trial, researchers selected about 45 pre-
menopausal women with a high risk of developing breast cancer 
(either with suspicious breast biopsies or former breast cancer 
survivors) and they gave them 50 mg of SDG lignan daily, or the 
equivalent of two spoons of powdered flaxseed. The research-
ers conducted needle biopsies on the breast tissue, both before 
and after the study, which lasted a year. Results showed that, 
on average, women had less breast precancerous changes after 
a 1 year period of taking daily flaxseed lignans, than they had 
before they started being studied and also that 80% (36 out of 45) 
had a decrease in the Ki-67 levels––a biomarker that signals the 
increase of cell proliferation. According to this clinical trial, SDG 
lignan can reduce the risk of breast cancer (60).
Some studies showed no association between risk of breast 
cancer and serum enterolactone levels (54, 55, 61, 62). There is 
a study that indicates a decreased breast cancer mortality with 
higher serum enterolactone levels (63). In a meta-analysis study, 
it was found that enterolactone biomarkers were associated with a 
statistically significant reduction of 28% in risk of postmenopau-
sal breast cancer (64). A study including 1,140 postmenopausal 
patients with breast cancer showed that serum enterolactone con-
centrations in the highest quartile were associated with a reduc-
tion of approximately 40% in mortality (65). Also, a case-control 
study concluded that a greater amount of serum enterolactone 
levels can be associated with a decreased breast cancer risk (66). 
It is necessary to conduct more studies to be able to confirm if 
there is an association between serum enterolactone levels and 
breast cancer risk.
Five studies published between 2010 and 2011, which included 
patients diagnosed with breast cancer who were observed for a 
period of 6–10 years, with the aim of finding out if lignans could 
prolong the survival of patients with breast cancer. Through the 
measurement of food records or of serum lignan levels, research-
ers concluded that there was an increased exposure to lignans, 
which led to a significant reduction of approximately 40–53% in 
mortality and a 33–70% reduction in mortality by breast cancer. 
This increased exposure to lignans was mostly observed in 
postmenopausal women. There is a possibility that lignans could 
prolong the lifespan of patients with breast cancer, but further 
studies are needed to confirm this (15, 56).
Breast cancer survivors who have higher levels of lignans in 
their bloodstream and on their diet seem to survive for a signifi-
cantly longer period of time (56, 65).
DiSCUSSiON
Since breast cancer has been considered one of the most common 
cancers with the highest mortality rate worldwide, it is important 
to include nutrition as part of this disease treatment. With the 
improvement in eating habits and the practice of physical activity, 
more than 30% of the cancers diagnosed could be avoided. It has 
been shown that an individualized nutritional intervention can 
reduce treatment complications and can improve the patients’ life 
quality. Flaxseed has been a vastly studied food due to the relation 
that it may have with breast cancer. Some experimental studies 
have been conducted in animals, but only a few clinical trials have 
been done in humans with the aim of discovering the effects of 
flaxseed on tumors and on the risk of this type of cancer.
Some studies revealed that the ingestion of omega-3 fatty acids 
is associated with the reduction of breast cancer. Animal studies 
showed that ALA can decrease the growth, size, and cell prolifera-
tion and can increase the death of breast tumor cells.
The majority of experimental studies conducted showed that 
flaxseed increases or maintains tamoxifen’s efficacy on the decrease 
of tumor growth on cell proliferation and on the increase of apopto-
sis. It is however necessary to conduct more clinical trials to confirm 
the association and respective efficacy of flaxseed with tamoxifen.
In several experimental studies, diets including 5 or 10% of 
flaxseed (approximately 25–30  g of flaxseed daily, in humans) 
inhibited the growth of the ER+ in human breast cancer cells 
injected in mice. The same happened with the growth of the ER−. 
Flaxseed also reduced the metastasis of ER− breast tumor.
During clinical trials, researchers have concluded that flaxseed 
has the potential to reduce the growth of tumors in patients with 
breast cancer, mainly postmenopausal women, and decrease the 
risk of this type of cancer.
Although many of the studies reported in this paper concluded 
that flaxseed intake may be related to the decreased risk of breast 
cancer and also to the reduction of the tumor’s growth and size, 
some studies including premenopausal and postmenopausal 
women did not show the same results.
However, more studies are still necessary, especially clinical 
trials, to verify the benefits of flaxseed on the treatment of breast 
cancer.
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